Annovis Bio Plunges 10.13% on Analyst Price Target Cut

On June 25, 2025, Annovis Bio's stock experienced a significant drop of 10.13% in pre-market trading, reflecting a notable shift in investor sentiment.

Analysts at H.C. Wainwright have revised their price target for Annovis Bio, setting it at $12. This adjustment comes amidst a broader reassessment of the company's prospects, which has influenced the stock's performance.

Annovis Bio currently holds an average brokerage recommendation of 1.80 on a scale of 1 to 5, indicating a generally positive outlook from analysts. This rating, which ranges from Strong Buy to Strong Sell, suggests that while there is optimism, recent developments have led to a more cautious stance.